{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:48:57Z","timestamp":1767865737174,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1124\/jpet.122.001151","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T09:55:51Z","timestamp":1654854951000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological Evaluation of a Pegylated Urocortin-1 Peptide in Experimental Autoimmune Disease Models"],"prefix":"10.1016","volume":"382","author":[{"given":"Josef G.","family":"Heuer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana E.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Geiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Hamang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannan","family":"Thirunavukkarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Alsina-Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei L.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001151_bib1","first-page":"E757","article-title":"Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin","volume":"275","author":"Agnello","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.122.001151_bib2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0016-5085(99)70491-9","article-title":"Urocortin reduces food intake and gastric emptying in lean and ob\/ob obese mice","volume":"116","author":"Asakawa","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.122.001151_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MED.0b013e3282f15407","article-title":"Glucocorticoid-induced osteoporosis","volume":"14","author":"Berris","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1124\/jpet.122.001151_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2337\/db18-1237","article-title":"Modified UCN2 peptide acts as an insulin sensitizer in skeletal muscle of obese mice","volume":"68","author":"Borg","year":"2019","journal-title":"Diabetes"},{"key":"10.1124\/jpet.122.001151_bib5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcsm.12746","article-title":"Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance","volume":"12","author":"Borg","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1124\/jpet.122.001151_bib6","first-page":"E152","article-title":"Effects of adrenalectomy and corticosterone administration on hypothalamic obesity in rats","volume":"243","author":"Bruce","year":"1982","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.122.001151_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/74255","article-title":"Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2","volume":"24","author":"Coste","year":"2000","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.122.001151_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2003-031231","article-title":"Urocortin-1 infusion in normal humans","volume":"89","author":"Davis","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.122.001151_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874467210666170109164430","article-title":"The multi-faceted profile of corticotropin-releasing factor (CRF) family of neuropeptides and of their receptors on the paracrine\/local regulation of the inflammatory response","volume":"11","author":"Dermitzaki","year":"2018","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/jpet.122.001151_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.steroids.2016.10.008","article-title":"Continuous corticosterone delivery via the drinking water or pellet implantation: a comparative study in mice","volume":"116","author":"Gasparini","year":"2016","journal-title":"Steroids"},{"key":"10.1124\/jpet.122.001151_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88322","article-title":"One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance","volume":"1","author":"Gao","year":"2016","journal-title":"JCI Insight"},{"key":"10.1124\/jpet.122.001151_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/gut.2005.084525","article-title":"Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn\u2019s disease","volume":"55","author":"Gonzalez-Rey","year":"2006","journal-title":"Gut"},{"key":"10.1124\/jpet.122.001151_bib13","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2353\/ajpath.2006.051104","article-title":"Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response","volume":"168","author":"Gonzalez-Rey","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.122.001151_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/art.22394","article-title":"Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells","volume":"56","author":"Gonzalez-Rey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.122.001151_bib15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/jpet.122.001151_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1874467210666170110125747","article-title":"CRH receptor signalling: potential roles in pathophysiology","volume":"10","author":"Grammatopoulos","year":"2017","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/jpet.122.001151_bib17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2174\/0929867054039008","article-title":"The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications","volume":"12","author":"Gravanis","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.122.001151_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41598-017-18401-y","article-title":"Murine splenic B cells express corticotropin-releasing hormone receptor 2 that affect their viability during a stress response","volume":"8","author":"Harl\u00e9","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001151_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.peptides.2004.05.024","article-title":"Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system","volume":"25","author":"Hashimoto","year":"2004","journal-title":"Peptides"},{"key":"10.1124\/jpet.122.001151_bib20","series-title":"An Overview of Glucocorticoid-Induced Osteoporosis.","author":"Ilias","year":"2022"},{"key":"10.1124\/jpet.122.001151_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1124\/jpet.102.047712","article-title":"Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat","volume":"305","author":"Inoue","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001151_bib22","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.peptides.2006.01.003","article-title":"Modifications of the human urocortin 2 peptide that improve pharmacological properties","volume":"27","author":"Isfort","year":"2006","journal-title":"Peptides"},{"key":"10.1124\/jpet.122.001151_bib23","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00125-011-2205-6","article-title":"Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet","volume":"54","author":"Jamieson","year":"2011","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.122.001151_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224428","article-title":"Significant alteration of liver metabolites by AAV8.Urocortin 2 gene transfer in mice with insulin resistance","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001151_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0149-7634(88)80071-X","article-title":"Glucocorticoids and hypothalamic obesity","volume":"12","author":"King","year":"1988","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.122.001151_bib26","first-page":"R699","article-title":"Role of corticosterone in TNF and IL-6 production in isolated perfused rat liver","volume":"268","author":"Liao","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.122.001151_bib27","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1210\/endo.136.9.7544278","article-title":"CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues","volume":"136","author":"Lovenberg","year":"1995","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.122.001151_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000216184","article-title":"Regulation of the hypothalamic-pituitary-adrenal axis","volume":"16","author":"Papadimitriou","year":"2009","journal-title":"Neuroimmunomodulation"},{"key":"10.1124\/jpet.122.001151_bib29","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1476-5381.2012.01904.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep","volume":"166","author":"Patel","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.122.001151_bib30","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.4049\/jimmunol.158.12.5751","article-title":"Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system","volume":"158","author":"Poliak","year":"1997","journal-title":"J Immunol"},{"key":"10.1124\/jpet.122.001151_bib31","doi-asserted-by":"crossref","first-page":"n1380","DOI":"10.1136\/bmj.n1380","article-title":"Glucocorticoid induced adrenal insufficiency","volume":"374","author":"Prete","year":"2021","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001151_bib32","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1161\/CIRCULATIONAHA.105.561308","article-title":"Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure","volume":"112","author":"Rademaker","year":"2005","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001151_bib33","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.162.5.3013","article-title":"Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells","volume":"162","author":"Radulovic","year":"1999","journal-title":"J Immunol"},{"key":"10.1124\/jpet.122.001151_bib34","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001151_bib35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000126276","article-title":"Mutually antagonistic effects of corticosterone and prolactin on rat lymphocyte proliferation","volume":"56","author":"Sandi","year":"1992","journal-title":"Neuroendocrinology"},{"key":"10.1124\/jpet.122.001151_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0165-2478(88)90061-2","article-title":"Binding of [125I]corticotropin releasing factor to blood immunocytes and its reduction in Alzheimer\u2019s disease","volume":"18","author":"Singh","year":"1988","journal-title":"Immunol Lett"},{"key":"10.1124\/jpet.122.001151_bib37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0022-3565(24)38092-9","article-title":"Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors","volume":"288","author":"Singh","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001151_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000328636","article-title":"Neuropeptides as pleiotropic modulators of the immune response","volume":"94","author":"Souza-Moreira","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1124\/jpet.122.001151_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13028-019-0480-2","article-title":"Urocortins in the mammalian endocrine system","volume":"61","author":"Squillacioti","year":"2019","journal-title":"Acta Vet Scand"},{"key":"10.1124\/jpet.122.001151_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00774-014-0578-6","article-title":"Effect of Urocortin on strength and microarchitecture of osteopenic rat femur","volume":"33","author":"Tezval","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"10.1124\/jpet.122.001151_bib41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000026380","article-title":"Urocortin and inflammation: confounding effects of hypotension on measures of inflammation","volume":"6","author":"Torpy","year":"1999","journal-title":"Neuroimmunomodulation"},{"key":"10.1124\/jpet.122.001151_bib42","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.febslet.2005.06.057","article-title":"Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2","volume":"579","author":"Tsatsanis","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.122.001151_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jcp.20900","article-title":"Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2","volume":"210","author":"Tsatsanis","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1124\/jpet.122.001151_bib44","first-page":"753","article-title":"The role of urocortins in the cardiovascular system","volume":"65","author":"Walczewska","year":"2014","journal-title":"J Physiol Pharmacol"},{"key":"10.1124\/jpet.122.001151_bib45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/endo-127-1-440","article-title":"Corticotropin-releasing factor receptors in mouse spleen: identification of receptor-bearing cells as resident macrophages","volume":"127","author":"Webster","year":"1990","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.122.001151_bib46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/ki.1988.126","article-title":"Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome","volume":"33","author":"Wetzels","year":"1988","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.122.001151_bib47","series-title":"Corticosteroid Adverse Effects","author":"Yasir","year":"2021"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:16:31Z","timestamp":1739970991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0022356524003185"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001151","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Evaluation of a Pegylated Urocortin-1 Peptide in Experimental Autoimmune Disease Models","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}